Recent Updates — PROK

ProKidney Corp. disclosed that its cash, cash equivalents, and marketable securities totaled $141.9 million as of September 30, 2026. The company also furnished an updated investor presentation detailing the ongoing Phase 3 PROACT 1 trial for rilparencel, a potential first-in-class autologous cell therapy for advanced chronic kidney disease. Topline data for the trial's surrogate endpoint is expected in Q2 2027, with current cash reserves projected to fund operations into mid-2027. ProKidney Corp. operates as a biotechnology company developing regenerative medicine therapies.

ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $200 million of its Class A common stock in at-the-market offerings. The company has no obligation to sell any shares and may suspend the offering at any time. Jefferies will receive compensation of up to 3.0% of gross proceeds plus specified expenses. This offering is subject to the effectiveness of a shelf registration statement on Form S-3 filed concurrently with this report. ProKidney Corp. operates in the biotechnology industry, focusing on developing therapies for kidney disease.